144 related articles for article (PubMed ID: 24357337)
1. Safety and efficacy of aprepitant for chemotherapy-induced nausea and vomiting in pediatric patients: a prospective, observational study.
Bodge M; Shillingburg A; Paul S; Biondo L
Pediatr Blood Cancer; 2014 Jun; 61(6):1111-3. PubMed ID: 24357337
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
Warr DG; Hesketh PJ; Gralla RJ; Muss HB; Herrstedt J; Eisenberg PD; Raftopoulos H; Grunberg SM; Gabriel M; Rodgers A; Bohidar N; Klinger G; Hustad CM; Horgan KJ; Skobieranda F
J Clin Oncol; 2005 Apr; 23(12):2822-30. PubMed ID: 15837996
[TBL] [Abstract][Full Text] [Related]
3. Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy.
Gao HF; Liang Y; Zhou NN; Zhang DS; Wu HY
Intern Med J; 2013 Jan; 43(1):73-6. PubMed ID: 22141732
[TBL] [Abstract][Full Text] [Related]
4. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
[TBL] [Abstract][Full Text] [Related]
5. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study.
Rapoport BL; Jordan K; Boice JA; Taylor A; Brown C; Hardwick JS; Carides A; Webb T; Schmoll HJ
Support Care Cancer; 2010 Apr; 18(4):423-31. PubMed ID: 19568773
[TBL] [Abstract][Full Text] [Related]
6. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F;
Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant.
Grote T; Hajdenberg J; Cartmell A; Ferguson S; Ginkel A; Charu V
J Support Oncol; 2006 Sep; 4(8):403-8. PubMed ID: 17004515
[TBL] [Abstract][Full Text] [Related]
8. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
[TBL] [Abstract][Full Text] [Related]
9. Aprepitant use in children, adolescents, and young adults for the control of chemotherapy-induced nausea and vomiting (CINV).
Choi MR; Jiles C; Seibel NL
J Pediatr Hematol Oncol; 2010 Oct; 32(7):e268-71. PubMed ID: 20736848
[TBL] [Abstract][Full Text] [Related]
10. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
Chawla SP; Grunberg SM; Gralla RJ; Hesketh PJ; Rittenberg C; Elmer ME; Schmidt C; Taylor A; Carides AD; Evans JK; Horgan KJ
Cancer; 2003 May; 97(9):2290-300. PubMed ID: 12712486
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of aprepitant in patients receiving high-dose chemotherapy with hematopoietic stem cell support.
Paul B; Trovato JA; Thompson J; Badros AZ; Goloubeva O
J Oncol Pharm Pract; 2010 Mar; 16(1):45-51. PubMed ID: 19525301
[TBL] [Abstract][Full Text] [Related]
12. Acute and delayed nausea and emesis control in pediatric oncology patients.
Holdsworth MT; Raisch DW; Frost J
Cancer; 2006 Feb; 106(4):931-40. PubMed ID: 16404740
[TBL] [Abstract][Full Text] [Related]
13. Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier oncology group study.
Albany C; Brames MJ; Fausel C; Johnson CS; Picus J; Einhorn LH
J Clin Oncol; 2012 Nov; 30(32):3998-4003. PubMed ID: 22915652
[TBL] [Abstract][Full Text] [Related]
14. Prevention of nausea and vomiting associated with stem cell transplant: results of a prospective, randomized trial of aprepitant used with highly emetogenic preparative regimens.
Stiff PJ; Fox-Geiman MP; Kiley K; Rychlik K; Parthasarathy M; Fletcher-Gonzalez D; Porter N; Go A; Smith SE; Rodriguez TE
Biol Blood Marrow Transplant; 2013 Jan; 19(1):49-55.e1. PubMed ID: 22863840
[TBL] [Abstract][Full Text] [Related]
15. Health outcomes and cost-effectiveness of aprepitant in outpatients receiving antiemetic prophylaxis for highly emetogenic chemotherapy in Germany.
Lordick F; Ehlken B; Ihbe-Heffinger A; Berger K; Krobot KJ; Pellissier J; Davies G; Deuson R
Eur J Cancer; 2007 Jan; 43(2):299-307. PubMed ID: 17134890
[TBL] [Abstract][Full Text] [Related]
16. Aprepitant as salvage therapy in patients with chemotherapy-induced nausea and emesis refractory to prophylaxis with 5-HT(3) antagonists and dexamethasone.
Oechsle K; Müller MR; Hartmann JT; Kanz L; Bokemeyer C
Onkologie; 2006 Dec; 29(12):557-61. PubMed ID: 17202825
[TBL] [Abstract][Full Text] [Related]
17. Differential time course of action of 5-HT3 and NK1 receptor antagonists when used with highly and moderately emetogenic chemotherapy (HEC and MEC).
Hesketh PJ; Warr DG; Street JC; Carides AD
Support Care Cancer; 2011 Sep; 19(9):1297-302. PubMed ID: 20623144
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy.
Herrstedt J; Muss HB; Warr DG; Hesketh PJ; Eisenberg PD; Raftopoulos H; Grunberg SM; Gabriel M; Rodgers A; Hustad CM; Horgan KJ; Skobieranda F;
Cancer; 2005 Oct; 104(7):1548-55. PubMed ID: 16104039
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy.
Warr DG; Street JC; Carides AD
Support Care Cancer; 2011 Jun; 19(6):807-13. PubMed ID: 20461438
[TBL] [Abstract][Full Text] [Related]
20. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
Schwartzberg L; Jackson J; Jain G; Balu S; Buchner D
Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):481-8. PubMed ID: 21711119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
